Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database
Küçük Resim Yok
Tarih
2021
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Future Medicine
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Aim: The authors present real-world data on the efficacy and safety of nivolumab in patients with metastatic renal cell carcinoma (mRCC). Methods: The Turkish Oncology Group Kidney Cancer Consortium (TKCC) database includes patients with mRCC from 13 cancer centers in Turkey. Patients with mRCC treated with nivolumab in the second line and beyond were extracted from the TKCC database. Results: A total of 173 patients were included. The rates of patients treated with nivolumab in the second, third, fourth and fifth lines were 47.4%, 32.4%, 14.5% and 5.7%, respectively. The median overall survival and progression-free survival were 24.2 months and 9.6 months, respectively. Nivolumab was discontinued owing to adverse events in 11 (6.4%) patients. Conclusion: Nivolumab was effective in patients with mRCC and no new safety signal was observed.
Açıklama
Anahtar Kelimeler
Immunotherapy, Kidney Cancer, Nivolumab, Renal Cell Carcinoma
Kaynak
Future Oncol .
WoS Q Değeri
Q3
Scopus Q Değeri
N/A
Cilt
Sayı
Künye
Yekedüz, E., Ertürk, İ., Tural, D., Karadurmuş, N., Karakaya, S., Hızal, M., Arıkan, R., Arslan, Ç., Taban, H., Küçükarda, A., Öztaş, N. Ş., Sever, Ö. N., Uçar, G., Can, O., Nahit Şendur, M. A., Demirci, U., Kılıçkap, S., Çiçin, İ., Öksüzoğlu, B., Özgüroğlu, M., … Ürün, Y. (2021). Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database. Future oncology (London, England), 10.2217/fon-2021-0717. Advance online publication.
